Annex Advisory Services LLC Trims Position in Medpace Holdings, Inc. $MEDP

Key Points

• Annex Advisory Services LLC reduced its stake in Medpace Holdings by 3.8%, selling 3,769 shares, leaving it with approximately 0.33% of the company, valued at nearly $30 million.
• Analyst price targets for Medpace vary widely, with notable upgrades from firms like Robert W. Baird and Deutsche Bank, listing target prices between $430.00 and $490.00.
• Medpace reported earnings of $3.10 per share, beating estimates and showing a 14.2% revenue increase compared to the same quarter last year.

Annex Advisory Services LLC reduced its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 3.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 95,421 shares of the company's stock after selling 3,769 shares during the period. Annex Advisory Services LLC owned about 0.33% of Medpace worth $29,949,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Whittier Trust Co. grew its position in Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after acquiring an additional 35 shares in the last quarter. Benjamin Edwards Inc. boosted its holdings in Medpace by 3.1% in the 1st quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company's stock valued at $366,000 after purchasing an additional 36 shares during the period. Geneos Wealth Management Inc. boosted its holdings in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after purchasing an additional 37 shares during the period. Assetmark Inc. raised its stake in shares of Medpace by 24.9% in the 1st quarter. Assetmark Inc. now owns 216 shares of the company's stock valued at $66,000 after buying an additional 43 shares in the last quarter. Finally, Proficio Capital Partners LLC increased its position in shares of Medpace by 6.4% during the 1st quarter. Proficio Capital Partners LLC now owns 777 shares of the company's stock worth $237,000 after purchasing an additional 47 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Medpace

In other news, CFO Kevin M. Brady sold 12,000 shares of Medpace stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the sale, the chief financial officer directly owned 6,000 shares in the company, valued at $2,725,380. The trade was a 66.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Susan E. Burwig sold 10,000 shares of Medpace stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total value of $4,800,000.00. Following the sale, the vice president owned 57,500 shares in the company, valued at $27,600,000. The trade was a 14.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 161,266 shares of company stock worth $74,111,427. 20.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Cowen lowered shares of Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. Barclays raised their target price on shares of Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. Mizuho raised their target price on shares of Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. William Blair reiterated a "market perform" rating on shares of Medpace in a report on Wednesday, July 23rd. Finally, Rothschild & Co Redburn downgraded shares of Medpace from a "buy" rating to a "neutral" rating and lifted their price objective for the company from $342.00 to $474.00 in a report on Wednesday, September 3rd. Two research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Reduce" and an average target price of $422.27.

Medpace Stock Performance

Shares of Medpace stock traded down $3.34 on Friday, reaching $498.60. 744,026 shares of the company's stock were exchanged, compared to its average volume of 316,492. The company has a market capitalization of $14.01 billion, a P/E ratio of 37.07, a price-to-earnings-growth ratio of 3.14 and a beta of 1.44. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $506.55. The firm's 50-day moving average is $446.89 and its two-hundred day moving average is $355.45.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The company had revenue of $603.31 million for the quarter, compared to analysts' expectations of $537.70 million. During the same period last year, the business earned $2.75 EPS. Medpace's quarterly revenue was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.